Key result
Lower serum fetuin-A levels in CKD patients were significantly correlated with higher vascular calcification scores, CIMT, and hs-CRP, and lower BMI and albumin (P<0.001 for most).
Why the study?
Fetuin-A is a circulating calcification inhibitor and marker of inflammatory-nutritional state, but its relationship with vascular calcification, CIMT, and nutritional and inflammatory markers across CKD stages needed evaluation.
Are serum fetuin-A levels associated with vascular calcification, intima-media thickness, and nutritional and inflammatory markers in patients with chronic kidney disease?
Cross-Sectional (n=238)
Are serum fetuin-A levels associated with vascular calcification, intima-media thickness, and nutritional and inflammatory markers in patients with chronic kidney disease?
p-value: p=<0.001
Lower levels of fetuin-A are associated with higher vascular calcification, CIMT, and inflammation, suggesting fetuin-A deficiency may be a key element for MIAC syndrome in CKD patients.
Fetuin-A associations with calcification in CKD are hypothesis-generating; leaves open its value as a biomarker or therapeutic target.
Background/aim: Fetuin-A, a circulating inhibitor of calcification, is a marker of inflammatory-nutritional state. We evaluated the association between serum fetuin-A levels and vascular calcification, intima-media thickness, and nutritional and inflammatory markers in different stages of chronic kidney disease (CKD). Materials and methods: CKD patients were sampled for calcium-phosphate parameters and nutritional and inflammatory markers [highly sensitive C-reactive protein (hs-CRP)], and serum fetuin-A levels. Intima-media thicknesses of the common carotid arteries (CIMT) were measured. Peripheral artery calcification scores were obtained. Results: A total of 238 patients were included in the study. Fetuin-A levels in patients with end-stage renal disease were significantly lower than those in patients with stage-3 and stage-4 CKD (stage-5 vs. stage-4, P < 0.001; stage-5 vs. stage-3, P < 0.001). Fetuin-A was negatively correlated with creatinine (P < 0.001), Ca × P product (P < 0.001), hs-CRP (P = 0.01), vascular calcification score (P < 0.001), and CIMT (P < 0.001), and positively correlated with BMI (P < 0.001, r = 0.30) and serum albumin (P < 0.001). Conclusion: Lower levels of fetuin-A were associated with higher vascular calcification scores, CIMT, hs-CRP levels, and lower BMI and albumin. Fetuin-A deficiency may be a key element for MIAC syndrome.
No takes yet. Share an insight, caveat, or question.
Mutluay et al. (2019) conducted a cross-sectional in chronic kidney disease (n=238). Serum fetuin-A was evaluated on Correlation of fetuin-A with vascular calcification score, CIMT, hs-CRP, BMI, and serum albumin (p=<0.001). Lower serum fetuin-A levels in CKD patients were significantly correlated with higher vascular calcification scores, CIMT, and hs-CRP, and lower BMI and albumin (P<0.001 for most).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: